Capital News

Non-Hodgkin Lymphoma Pipeline Assessment, Key Companies And Emerging Drugs

 Breaking News
  • No posts were found

Non-Hodgkin Lymphoma Pipeline Assessment, Key Companies And Emerging Drugs

August 31
20:26 2020
Non-Hodgkin Lymphoma Pipeline Assessment, Key Companies And Emerging Drugs

“Non-Hodgkin Lymphoma Pipeline Insight, 2020” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Non-Hodgkin Lymphoma market.

“Non-Hodgkin Lymphoma Pipeline Insight, 2020” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Non-Hodgkin Lymphoma market.

The Non-Hodgkin Lymphoma Pipeline report embraces in-depth analysis of commercial assessment and clinical assessment of the Non-Hodgkin Lymphoma pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Non-Hodgkin Lymphoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Get FREE sample copy at: 

https://www.delveinsight.com/sample-request/non-hodgkins-lymphoma-nhl-pipeline-insight

 non-hodgkins-lymphoma-nhl-pipeline-insight

The dynamics of the NHL market is anticipated to change in the coming years owing to the launch of emerging therapies during the forecast period of 2020–2030. Major Pharma giants are thoroughly working toward the development of new treatment therapies for this indication, in order to provide better relief for the symptoms and hence improve the Quality of life (QoL) of patients with NHL. Some of the Key players involved in developing therapies for NHL includes:

Bristol-Myers Squibb
Gilead Sciences
MorphoSys AG
Epizyme
TG Therapeutics
Pfizer/Merck
Xynomic Pharmaceuticals
BeiGene
Hoffmann-La Roche
AbbVie
Novartis
Verastem
Merck Sharp & Dohme
Gilead Sciences
Bayer
AstraZeneca
And several others

 

Drugs Covered
Tafasitamab (MOR208; formerly XmAb 5574)
Lisocabtagene maraleucel (JCAR017)
Enzastaurin Hydrochloride (DB102)
Avelumab (Bavencio)
Umbralisib (TG-1202)
And many others.

 

Non-Hodgkin Lymphoma Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Non-Hodgkin Lymphoma with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Non-Hodgkin Lymphoma treatment.

  • Non-Hodgkin Lymphoma key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Non-Hodgkin Lymphoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.  

 

Scope of the report

  • The Non-Hodgkin Lymphoma Report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Non-Hodgkin Lymphoma across the complete product development cycle, including all clinical and nonclinical stages.

  • It comprises of detailed profiles of Non-Hodgkin Lymphoma therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details

  • Detailed Non-Hodgkin Lymphoma research and development progress and trial details, results wherever available, are also included in the pipeline study.

  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Non-Hodgkin Lymphoma.

 

Report Highlights

A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Non-Hodgkin Lymphoma.    

In the coming years, the Non-Hodgkin Lymphoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. 

The companies and academics that are working to assess challenges and seek opportunities that could influence Non-Hodgkin Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

A detailed portfolio of major pharma players who are involved in fueling the Non-Hodgkin Lymphoma treatment market. Several potential therapies for Non-Hodgkin Lymphoma are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Non-Hodgkin Lymphoma market size in the coming years.  

Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Non-Hodgkin Lymphoma) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities. 

 

Table of Content

1. Report Introduction

2. Non-Hodgkin Lymphoma 

3. Non-Hodgkin Lymphoma Current Treatment Patterns

4. Non-Hodgkin Lymphoma – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Non-Hodgkin Lymphoma Late Stage Products (Phase-III)

7. Non-Hodgkin Lymphoma Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Non-Hodgkin Lymphoma Discontinued Products

13. Non-Hodgkin Lymphoma Product Profiles

14. Non-Hodgkin Lymphoma Key Companies

15. Non-Hodgkin Lymphoma Key Products

16. Dormant and Discontinued Products

17. Non-Hodgkin Lymphoma Unmet Needs

18. Non-Hodgkin Lymphoma Future Perspectives

19. Non-Hodgkin Lymphoma Analyst Review  

20. Appendix

21. Report Methodology

 

Related Reports

Non-Hodgkin’s Lymphoma Market Insight, Epidemiology and Market Forecast -2030

DelveInsight’s “Non-Hodgkin’s Lymphoma Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Non-Hodgkin’s Lymphoma, historical and forecasted epidemiology as well as the Non-Hodgkin’s Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Non-Hodgkin’s Lymphoma (NHL) Epidemiology Forecast to 2030

DelveInsight’s Non-Hodgkin’s Lymphoma (NHL) Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Non-Hodgkin’s Lymphoma (NHL) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/capitalnews/public_html/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share